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Abstract 
Neuropathic pain is a debilitating pathological condition of high clinical relevance. Changes in 
neuronal excitability in the anterior cingulate cortex (ACC) play a central role in the negative 
emotional and affective aspects of chronic pain. We evaluated the effects of LP-211, a new 
serotonin-receptor-type-7 (5-HT7R) agonist that crosses the blood-brain barrier, on ACC neurons in 
a mouse model of neuropathic pain. LP-211 reduced synaptic integration in layer 5 pyramidal 
neurons, which was enhanced in neuropathic pain due to a dysfunction of dendritic 
hyperpolarization-activated-and-cyclic-nucleotide-regulated (HCN) channels. Acute injection of 
LP-211 had an analgesic effect, increasing the mechanical withdrawal threshold in neuropathic 
animals, which was partially mediated by an action in the ACC. Additionally, the acute application 
of LP-211 blocked the switch in the place escape/avoidance behavior induced by noxious stimuli. 
Thus systemic treatment with a 5-HT7R agonist leads to modulation of the ACC, which dampens 
sensory and affective aspects of chronic pain.  
 
Key words: Neuropathic pain, anterior cingulate cortex, HCN channels, pyramidal neuron 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
3 
1. Introduction 
The anterior cingulate cortex (ACC) is one of the key brain regions for the processing of pain 
(Basbaum et al., 2009; Devinsky et al., 1995; Zhuo, 2008). It is associated with encoding the 
emotional and aversive aspects of pain and it might be linked to the comorbid symptoms of chronic 
pain like depression (Barthas et al., 2015), lack of motivation (Navratilova and Porreca, 2014) and 
anxiety (Zhuo, 2016). Changes in the neuronal activity in this brain area are thought to be causally 
linked to the development of neuropathic pain (Baliki et al., 2012). Accordingly, hyperactivity has 
been observed in the human ACC in chronic pain states (Apkarian et al., 2009). On the cellular and 
network level a number of plastic changes induced by neuropathic pain have been described in the 
ACC ranging from increased cellular excitability and network restructuring (Blom et al., 2014) to 
malfunctioning synaptic plasticity mechanisms to promote hyperexcitability (Li et al., 2010). 
Recently we found that neuropathic pain causes a functional downregulation of hyperpolarization-
activated-and-cyclic-nucleotide-regulated (HCN) channels in the dendrites of layer 5 (L5) 
pyramidal neurons in the ACC leading to cellular hyperexcitability due to enhanced dendritic 
integration of excitatory postsynaptic potentials (EPSPs) (Santello and Nevian, 2015). This 
malfunction of HCN channels in pyramidal neurons in the chronic pain condition was recently 
confirmed by a number of studies (Cordeiro Matos et al., 2015; Gao et al., 2016). 
Therefore, targeting the ACC for a recovery of the pathologically enhanced neuronal activity might 
be a valid strategy to alleviate the emotional aspects of the neuropathic pain condition (Zhuo, 
2008). Several pharmacological interventions or neuronal manipulations in the ACC have been 
proven effective in alleviating neuropathic pain behaviors (Gu et al., 2015; Li et al., 2010; Qu et al., 
2011; Santello and Nevian, 2015). Particularly, approaches that utilize the brain’s neuromodulatory 
systems might be a promising strategy for pain treatment without interfering with other essential 
signaling pathways in the brain (Santello and Nevian, 2015). Yet, a way to achieve 
neuromodulation in the ACC in behaving animals in a non-invasive manner is still lacking. We 
took advantage of the new brain penetrant 5-HT7 receptor agonist LP-211 (Adriani et al., 2012; 
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Hedlund et al., 2010; Leopoldo et al., 2008) to modulate ACC neuronal activity and to evaluate its 
potential therapeutical effect on neuropathic pain behaviors. 
 
2. Materials and methods 
2.1 Neuropathic pain model  
All the experiments were conducted after the approval of the Bern cantonal veterinary office 
(Switzerland). Only adult C57BL/6 male mice (8-12 weeks) were used. Mice were housed in 
groups of 5 in non-filtered cages, with a non-inverted 12 h day-night cycle and food/drink ad 
libitum. Mice were deeply anesthetized (Isoflurane) and then maintained with lower anesthesia 
concentration (1-1.5 %) during the surgery. The surgeries were conducted under a sterile hood with 
laminar air flow. Temperature was maintained constant using an electric heating pad with rectal 
probe. The eyes were maintained humidified with the application of eye drops (Alcon, 
Switzerland). After the removal of the fur with a depilatory cream (Veet, Reckitt Benckiser, 
Switzerland), an incision on the left posterior thigh was made to allow the Chronic Constriction 
Injury of the exposed sciatic nerve through three loose ligations 1 mm apart (5-0 Sofsilk tread - US 
Surgicals). Animals whose nerve was exposed but left untouched were used as control group 
(Sham). The wound was sutured using 4-0 coated VICRYL rapid suture (Ethicon). The animals 
recovered from the surgery after ~5 min and did not receive any postoperative analgesic treatment. 
2.2 Von Frey test  
The mechanical sensitization caused by CCI surgery was assessed using the electronic Von Frey 
filament test (IITC Life Science). To record the mechanical threshold the mice were habituated in a 
room at 20-23 °C with basal noise levels on a metal grid for ~30 min and then tested with the 
application of the Von Frey filament on the central plantar paw until the spontaneous retraction was 
detected. Six measures per each paw were averaged to verify the development of the mechanical 
hyperalgesia. CCI mice were tested at -4, -1, +3, +6 days from the surgery.  
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Von Frey testing was used to assess the modulation of the mechanical hypersensitivity by LP-211 
treatment in the CCI pain model. In these experiments the animals were tested with the following 
time course: day -4, +7 relative to the surgery and +30, +60, +90, +120, +150, +180 min after the 
injection. When we performed the brain injection of SB-269970 together with i.p. injection of LP-
211 or saline, the time course followed with the Von Frey testing was -4, +7 days relative to the 
surgery and +30, +45, +60, +90, +120 min from the end of the brain injection. 
2.3 Acute brain slice preparation and patch-clamp electrophysiology 
300 µm-thick coronal ACC brain slices were obtained from CCI or Sham mice 7 to 10 days after 
the surgery. Anesthetized animals were decapitated and the brain was quickly removed from the 
skull and maintained in ice-cold oxygenated (95% O2 and 5% CO2) slicing solution (65 mM NaCl, 
2.5 mM KCl, 1.25 mM NaH2PO4, 25 mM NaHCO3, 7 mM MgCl2 , 0.5 mM CaCl2 , 25 mM 
glucose, and 105 mM sucrose) for the slicing procedure. Brains were mounted on a vibratome (HM 
650, Micron) inside a slicing chamber containing the same ice-cold solution. Slices were then 
transferred into aCSF solution (125 mM NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4, 25 mM NaHCO3, 
1 mM MgCl2, 2 mM CaCl2, and 25 mM glucose ) at 34°C for 45 min and then at room temperature 
until use. 
All the electrophysiological experiments were conducted on animals that were before tested with 
the electronic Von Frey filament and all the recordings were performed at 32-33 °C using aCSF as 
above. The recordings were conducted on rostroventral ACC pyramidal cell of the layer 5 (1.1-1.4 
mm below the pial surface, 1.1-0.2 mm rostral to the Bregma and contralateral to the lesion) with a 
Leica DMLFS microscope (63X water-immersion objective), oblique illumination and CCD 
camera. The selection of the pyramidal cells to patch was based on their somatic morphology and 
on the presence of clearly visible thick apical dendrite. Recording pipettes with a thick borosilicate 
wall (resistance 5–9 MΩ) were used. The dendritic patch clamp, always performed near the main 
apical bifurcation, was achieved with 15-17 MΩ pipettes with the same intracellular solution (130 
mM potassium gluconate, 5 mM KCl, 10 mM HEPES, 10 mM Na+-phosphocreatine, 4 mM Mg2+-
ATP, 0.3 mM Na+-GTP, 0.2% biocytin (pH 7.3)). Biocytin was used to allow the cell 
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reconstruction after PFA fixation (avidin-biotin-peroxidase method (Egger et al., 2008; Sieber et 
al., 2013)).  
Data were acquired with a Dagan BCV-700A amplifier (Dagan Corporation, Minneapolis, MN, 
USA). Signals were digitized with an ITC-18 board (HEKA Electronics, Lambrecht, Germany). 
Electrode capacitance and series resistance was compensated at the beginning of the recording and 
regularly checked and readjusted. Voltage was filtered at 5 kHz and digitalized at 10 kHz. Focal 
electrical synaptic stimulation was achieved by placing a theta patch-pipette located in the inner 
layer 1, 30-80 μm lateral to the main apical dendrite. Stimulation intensity was manually adjusted 
(usually 1-3 V) to obtain a stable baseline (average amplitude 5.42 ± 0.58 mV). LP-211 was bath-
applied at the concentration of 27 nM. After recording, pipettes were gently retracted and slices 
were placed in 4% paraformaldehyde (PFA). Slices were developed with the avidin-
biotinperoxidase method and mounted on cover slides. Neurolucida reconstructions were 
performed to reveal the morphology of the cells. Axonal projections were omitted. 
2.4 Immunohistochemistry and fluorescence imaging 
5-HT7 and HCN channels were co-stained to allow the visualization of the pattern of expression in 
the cortical layers of the ACC. Brain slices for fluorescent immunohistochemical double labeling 
were prepared from perfusion-fixed brains and staining procedures described by (Nolan et al., 
2007; Santoro et al., 2009) were used. Animals were anaesthetized with ketamine/xylazine and 
cardially perfused with PBS, followed by 4% PFA diluted in PBS. Fixed brains were removed and 
postfixed in 4% PFA at 4° C overnight. After washing the brain with PBS (4x10 min), 50 um thick 
coronal brain slices were prepared and permeabilized in PBS containing 0.1% Triton-X100  
(3x10min). For double immunolabeling of HCN channels and 5HT7 receptors, slices were 
incubated for 1h in a blocking buffer containing 5% normal chicken serum (NCS) and then 
simultaneously incubated in goat polyclonal anti-HCN1 (Santa Cruz, sc-19706; 1:250) and rabbit 
polyclonal anti-5HT7 (Novus, NBP1-46598; 1:250) in NCS blocking buffer overnight. After 
primary incubation, slices were washed in PBS containing 0.1% Triton-X100 (3x10 min) and 
incubated in fluorescence conjugated secondary antisera (Alexa-594 chicken anti-goat IgG; Life 
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Technologies, A21468; 1:500 and Alexa-488 chicken anti-rabbit IgG; Life Technologies, A21441; 
1:100) in NCS blocking buffer at room temperature for 3h. After further washing with PBS 
containing 0.1% Triton-X100 (1x10 min) and washing in PBS (3x10 min), slices were embedded 
in UltraCruz mounting medium on microscopy slides. Fluorescently labeled coronal brain slices 
were imaged using a confocal microscope (Leica SP8) equipped with a white-light laser and two 
GaAsP-detectors (HyD). Imaging was performed with a 20x objective (Leica, HC PL APO, 20x, 
NA 0.75 IMM CORR CS2) from the rostral ACC. In control experiments, slices were treated 
similarly, but the primary antibodies were omitted. No unspecific staining was observed in this 
case. Specificity of the 5-HT7R antibody was further asserted by detecting no specific staining (i.e. 
of apical dendrites) in other selected brain areas.  
2.5 In vivo drug testing 
LP-211 was maintained in stock solution with ethanol and then used diluted in saline (NaCl 0.9%). 
SB-269970 was bilaterally injected in the brain (0.5 μl per injection site, 100 μM) in solution with 
Alexa-594 hydrazide (100 μM) and aCSF.  
All the pharmacological in-vivo treatments were performed on CCI animals tested with the Von 
Frey electronic filaments 7-10 days after the CCI surgery to verify the development of the 
mechanical allodynia and to find the reference baseline for the comparison with the drug effect. i.p. 
injections were performed in lightly anesthetize mice (1% Isoflurane) to avoid any stress which 
could have an impact on the behavioral result. Brain injections were preformed on isoflurane 
anesthetized animals (2%), which were head fixed to allow the incision of the scalp and the 
exposure of the skull. Two holes were drilled with a dental drill (Osada electronics, Tokyo, Japan) 
above the ACC (0.70 mm rostral and 0.35 mm lateral from Bregma,) or above the hindpaw S1 
region (-0.70 mm rostral and 1.95 mm lateral from Bregma). A micromanipulator was used to 
position the micropipette in place and an air pressure system was used to control the injection 
speed. Injections were performed at 1.95 mm depth from the skull for the ACC and 1 mm depth for 
S1 respectively. Injection site was post hoc verified by brain clearing and light sheet imaging 
(Santello and Nevian, 2015). 
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In the LP-211 + SB-269970 experiments, the i.p. injection of LP-211 was done 20 min before the 
brain injection of SB-269970. 
2.6 Place escape/avoidance paradigm  
Experiments were conducted on CCI mice 7-8 days after surgery between 10 a.m. and 15 p.m. The 
temperature of the behavior room was between 20-23 °C with a basal noise level. Always the same 
experimenter alone tested the animals. A cold light lamp pointing at the ceiling of the room was 
used to diffusely illuminate the room. An open-air custom built two compartment box (40.5 x 29.5 
x 25 cm) was used for the place escape/avoidance paradigm (PEAP) experiment. The box was 
positioned on a metal grid to allow for hind paw stimulation. One compartment had transparent 
walls and the other black walls. The two compartments were separated by a door of 7 x 7 cm 
allowing free movement of the mouse between the dark and light side. The illumination was set to 
180 LUX intensity. Some experiments were conducted at lower light intensity (~ 10 LUX) but we 
observed no difference in the resulting data. Thus, the two groups were pooled together. The 
bottom of the chamber was illuminated with an IR lamp (46 x 66 cm) allowing high contrast 
recording of the position of the animal by an IR camera. For each experiment the mouse was gently 
put inside the light compartment and the recording session was immediately started (total of 40 
min). The test consisted of 10 min recording of free exploration followed by 30 min of paw 
stimulation according to the chamber the animal was in. The hind paws were stimulated every 15 s 
with a Von Frey filament (number 12). The uninjured paw was stimulated in the light compartment 
and the injured paw was stimulated in the dark compartment. The entire course of the experiment 
was recorded and analysed using EthoVision XT (Noldus). The time spent in each compartment 
was determined in bins of 10 min and expressed as percentage of the time spent in the light 
compartment. The PEAP test of animals injected with LP-211 was started 1h 40 min after the 
injection of the drug in order to reach its peak effect during the behavioral test. 
2.7 Brain clearing  
Isoflurane anesthetized mice were decapitated and the extracted brain was briefly washed in PBS 
and post-fixed in PFA 4% for 2 days at 4 °C. After 3 washings of 10 minutes in PBS, we applied 
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9 
the dehydration protocol with series of 30%, 50%, 70%, 80%, 95% and twice 100% EtOH washes. 
The brains were then processed for the clearing treatment and 3D-ultramicroscopy imaging using a 
LaVision Lightsheet microscope(Santello and Nevian, 2015). 
2.8 Data analysis 
Electrophysiological recordings were acquired with IgorPro (Wavemetrics) and analyzed with 
custom written Igor procedures.  
The sag ratio was calculated with the equation sag ratio = (Vbaseline – Vmin) / (Vbaseline – Vsteady-state) 
where Vbaseline is the resting membrane potential, Vmin is the minimum voltage reached soon after 
the hyperpolarizing current pulse and Vsteady-state is the voltage recorded a few milliseconds before 
the end of the stimulus. For simplicity, Vmax refers to Vbaseline – Vmin and VSS (steady state) refers to 
Vbaseline – Vsteady-state in the figures.  
EPSP amplitude and integral and coefficient of variation (CV
2
) were evaluated by averaging 10 
seeps before and at least 15 minutes after LP-211 bath application (inter-stimulus interval 10 sec). 
Paired-pulse ratio was calculated by averaging 4 sweeps (inter-stimulus interval 20 sec). The 
inverse of the square CV was calculated by 1/CV
2
 = m
2/σ2, with m being the average EPSP 
amplitude and σ the SD. 
The antihyperalgesic drug effect was quantified from the ratio of the left to right hind paw 
withdrawal thresholds as follows: (Et−Epredrug)/ Epredrug with Et being the average ratio of the time 
points around the maximal antihyperalgesic effect. In particular, for the I.P. injection of LP-211 the 
2 h timepoint was considered and for the I.P. injection of LP-211 + SB/Saline in the ACC and S1 
the average between 30-45 min was considered.  
Acquisition of the PEAP experiments was performed with Noldus EthoVision XT software. A 
speed threshold (2.5 cm/s) was applied to the last ten minutes average of each acquisition session to 
verify that the animal had not been affected by the manipulation.  
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Statistical analysis was performed in Excel (Microsoft) and Prism (Graphpad) using paired or 
unpaired Student’s t-test and or one-way RM-ANOVA for in vivo drug injections. Statistical 
significance was assumed for p < 0.05. Error bars represent the standard error of the mean (SEM). 
2.9 Chemicals and Solutions used  
LP-211 (N-(4-cyanophenylmethyl)-4-(2-diphenyl)-1-piperazinehexanamide) was synthetized at the 
Department of Pharmacy, University of Bari "A. Moro" Bari, Italy and used for the in-vivo 
experiments at a concentration of 10 mg/kg and for patch-clamp experiments at 27 nM. A subset of 
PEAP experiments were conducted with 2.5 mg/kg LP-211 injection but the results did non differ 
from the 10 mg/kg concentration so they were pulled together for the statistical analysis. For the 
brain injection, the serotonin receptor antagonist (2R)-1-((3-Hydroxyphenyl)sulfonyl)-2-(2-(4-
methyl-1-piperidinyl)ethyl)pyrrolidine hydrochloride (SB-269970, Sigma) was used at 100 µM. 
Alexa-594 hydrazide was obtained from Life Technologies (A-10438). All the chemicals for the 
electrophysiology solutions were obtained from Tocris. 
 
3. Results 
3.1 The brain-penetrant 5-HT7R agonist LP-211 modulates dendritic HCN channels in ACC 
neurons 
HCN channels are highly enriched in the apical dendrites on layer 5 (L5) pyramidal cells 
throughout the neocortex and they are subjected to modulation by activation of several G protein 
coupled receptors (He et al., 2014; Postea and Biel, 2011). We have recently identified a specific 
receptor, the serotonin type 7 receptor (5-HT7R), which enhances dendritic HCN channel function 
of L5 pyramidal neurons in the ACC by elevating cAMP levels (Santello and Nevian, 2015).  
Immunohistochemical labeling of 5-HT7R and HCN1 revealed a co-localization in the apical 
dendrites of L5 pyramidal cells in the ACC (Fig. 1A,B), pointing to a functional coupling between 
5-HT7R activation and HCN channel modulation. Neuropathic pain caused by chronic constriction 
injury (CCI) of the left sciatic nerve results in a down regulation of HCN channels in the apical 
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dendrites (Santello and Nevian, 2015). We investigated if this pathological change concomitantly 
influenced the distribution of 5-HT7Rs. Within one week after the peripheral nerve ligation, CCI 
animals developed mechanical hypersensitivity restricted to the injured hind paw, which was not 
present in sham-operated mice (sham) (Fig. 1C). At this time point, we derived fluorescence 
intensity profiles from double immunohistochemical labeling of HCN channels and 5-HT7Rs from 
brain slices of sham (n = 9 slices from 4 animals) and CCI (n = 9 slices from 4 animals) animals. 
HCN channel labeling showed a characteristic decrease from distal to proximal dendritic 
compartments, which was well fitted by a single exponential. The corresponding fluorescence 
length constant HCN was significantly shorter in CCI as compared to sham animals (Fig. 1D, CCI 
36.4 ± 1.4 m, sham 46.0 ± 1.7 m; p < 0.001) confirming our previous results (Santello and 
Nevian, 2015). 5-HT7R labeling showed a Gaussian distribution in the distal apical dendrites with a 
peak in L2/3. The peak intensity and the width of this distribution were similar in CCI and sham 
(Fig. 1E, intensity: CCI 9.4 ± 1.2, sham 9.0 ± 1.4; p = 0.83; width: CCI 76.0 ± 6.1 m, sham 78.7 ± 
3.4 m; p = 0.74) suggesting no apparent plasticity of 5-HT7Rs. 
In order to test now if the novel, brain-penetrant and highly selective 5-HT7R agonist LP-211 has a 
similar modulatory effect on HCN channel function as previously shown with the less potent 5-
HT7R agonist 5-CT, we performed direct dendritic patch-clamp recordings in brain slices from the 
dendrites of L5 pyramidal neurons in the ACC of adult animals that had been subjected to CCI. 
Bath application of LP-211 induced a significant depolarization of the dendritic membrane 
potential  (baseline -66.16 ± 1.33 mV; LP-211 -64.96 ± 1.21 mV, n = 5; p < 0.05). In parallel, the 
voltage sag in response to a hyperpolarizing current step increased (baseline 1.37 ± 0.07, LP-211 
1.5 ± 0.08, n = 5; p < 0.05), indicating an enhancement of HCN channel function (Fig. 2A-C). 
Importantly, LP-211 had no influence on synaptic function, i.e. no influence on the amplitude or 
coefficient of variation of evoked EPSPs (Fig. 2D,E, amplitude: baseline 5.42 ± 0.57 mV, LP-211 
5.26 ± 0.56 mV; CV
2
: baseline 29.59 ± 1.14, LP-211 22.67 ± 4.06, n = 10; p > 0.05), suggesting no 
modulation of pre- and post-synaptic function by 5-HT7Rs. Instead, we noticed a reduction in the 
single EPSP integral (baseline 143 ± 16 ms·mV, LP-211 128 ± 16 ms·mV, n = 10; p < 0.05) as 
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well as a reduction in EPSP summation, evaluated from the paired-pulse ratio of two EPSPs 
evoked at 50 Hz (Fig. 2F, second/first amplitude: baseline 2.10 ± 1.0, LP-211 1.73 ± 0.12, n = 10; 
p < 0.05). These results suggested that activation of 5-HT7Rs by LP-211 lead to an increase in 
HCN channel function resulting in accelerated EPSP repolarization and a reduction in dendritic 
integration. 
 
3.2 LP-211 is more effective in modulation of HCN channels than 5-CT 
Bath application of LP-211 had a significant effect on the sag ratio measured with somatic whole-
cell recordings (Fig. 3A,B). We found an increase in the somatic sag ratio in these experiments 
(baseline 1.26 ± 0.02, LP-211 1.31 ± 0.02, n = 18; p < 0.05) that was not observed with the 5-HT7 
agonist 5-CT (baseline 1.27 ± 0.02, 5-CT 1.24 ± 0.02, n = 10; p = 0.08). Indeed, there was a 
significant difference between LP-211 and 5-CT in modulating the somatic sag ratio (Fig. 3D, LP-
211 1.04 ± 0.01, 5-CT 0.98 ± 0.01, p < 0.001). This suggests that LP-211 is more potent than 5-CT 
in modulating HCN channels. Furthermore, LP-211 increased the sag ratio in sham animals (Fig. 
3E, Sham+LP-211 1.05 ± 0.02, p < 0.05) to a similar extend as in CCI animals (p = 0.59). Thus, the 
coupling of 5-HT7Rs to HCN channels is independent from the pathological state. 
 
3.3 Systemic injection of LP-211 reduces mechanical hypersensitivity and it partially acts by 
modulation of the ACC 
Next, we tested if the reversal of the pathological condition that we observed on the cellular level 
by LP-211 in vitro had an influence on the pain behavior of neuropathic animals. LP-211 can 
readily cross the blood-brain-barrier and it has been shown to act in the central nervous system 
(Leopoldo et al., 2008). Testing the effect of LP-211 on mechanical hypersensitivity induced by 
CCI, we found that a single i.p. injection increased the mechanical withdrawal threshold whereas 
saline injections had no effect (Fig. 4A-D). The analgesic drug response was effective after 30 
minutes, reached a maximum between 90 and 150 min after injection and lasted at least 3 hours. 
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The maximal analgesic effect, expressed as the drug effect, was 0.58 ± 0.13 (n = 7) and 
significantly different from the saline injected controls (drug effect control: 0.04 ± 0.07, n = 6; p < 
0.01).   
These results illustrate the potential therapeutical utility of LP-211 as an analgesic drug, which can 
be systemically injected. Nevertheless, the site of action has yet to be determined. Our findings that 
5-HT7 receptors are highly enriched in the dendrites of L5 pyramidal neurons in the ACC and that 
they co-localize and are functionally coupled with HCN channels suggest an involvement of 
cortical sites to its action. To determine the contribution of the ACC to the analgesic effect of 
systemic injection of LP-211, we inhibited 5-HT7Rs specifically in the ACC by local injection of 
the selective antagonist SB-269970 together with systemic injection of LP-211 in CCI animals 
(Fig. 5). The block of 5-HT7Rs in the ACC lead to a substantial reduction of the analgesic effect of 
LP-211 (Fig. 5C-E, drug effect, LP-211+saline: 0.52 ± 0.08, n = 6; LP-211+SB269970: 0.29 ± 
0.08, n = 6; p < 0.05). Because local injections of SB-269970 per se did not reduce mechanical 
hypersensitivity (Fig. 5E, drug effect, saline: -0.03 ± 0.03 n = 4; SB-269970: 0.02 ± 0.04 n = 7), we 
concluded that LP-211 directly activated 5-HT7 receptors in the ACC reducing the response to 
mechanical stimulation of the injured hind paw. 
As a control for the specificity of the blocking action of SB-269970 in the ACC, saline or SB-
269970 was injected into the region of the hind paw representation in the primary somatosensory 
cortex (S1) after IP injection of LP-211 (Fig. 5F-H). S1 is another important area involved in pain 
processing and its modulation can influence pain behavior (Eto et al., 2011). In contrast to the 
effect on the ACC, injection of SB-269970 in S1 produced no change in the LP-211-induced 
reduction of mechanical hypersensitivity (drug effect, saline: 0.54 ± 0.14, n = 7; SB-269970: 0.51 ± 
0.08, n = 8; p = 0.41).  
In summary, these results confirmed that LP-211 crossed the blood-brain-barrier and that it exerted 
its effect partially in the ACC, but that it is not generally acting on cortical areas involved in pain 
processing as exemplified by the absence of modulation in S1. Modulation of other brain areas, for 
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example the PAG or the raphe nuclei, as well as an influence on the spinal cord, may account for 
the residual analgesic effect of the drug. 
 
3.4 LP-211 reverses the place escape/avoidance behavior in CCI animals 
The ACC is essential for the processing of the emotional/affective component of pain (Basbaum et 
al., 2009; Costigan et al., 2009; King et al., 2009; Navratilova and Porreca, 2014). We therefore 
tested if LP-211 was also able to modulate the affective aspects associated with neuropathic pain 
by using the place escape/avoidance paradigm (PEAP) (Fig. 6). This task requires processing in the 
ACC and it assesses the averseness of neuropathic pain by exploiting the conflict between the 
desire to avoid pain versus the safety of a preferred dark location (LaBuda and Fuchs, 2000; 
LaGraize et al., 2004). Animals were free to avoid a noxious stimulus given to the injured hind paw 
in the dark compartment by moving to the light compartment, where the contralateral paw was 
mechanically stimulated. Touching the corresponding paw was repeated every 15 s. Since LP-211 
reduced the mechanical withdrawal response as measured with the von-Frey test, we used a much 
more rigid filament (number 12) to clearly evoke a supra-threshold, nociceptive response in the 
injured, left hind paw. CCI animals injected i.p. with a saline solution showed a switch in the place 
preference from the dark to the light compartment (Fig. 6A,B). In contrast, CCI animals injected 
with LP-211 did not show this switch and they where not affected by the noxious stimulation in the 
dark compartment anymore (relative time in light compartment, 20-30 min after beginning of 
stimulation: saline: 48.2 ± 3.1%, n = 7; LP-211: 27.6 ± 3.4%, n = 8; p < 0.05). LP-211 had no 
effect on the spontaneous exploratory behavior evaluated within 10 min before the paws were 
stimulated (Fig. 6C; saline: 44.5 ± 3.7%; n = 7, LP-211: 43.9 ± 4.6%; n = 8; p > 0.05) ruling out 
general anxiolytic effects of LP-211 in this behavioral paradigm. Furthermore, LP-211 did not 
exert sedative effects on the animals since the average velocity (saline: 4.04 ± 0.38 cm/s; LP-211: 
3.49 ± 0.37 cm/s; p > 0.05) and total distance covered (saline: 74.84 ± 1.25 m; LP-211: 77.44 ± 
0.80 m; p > 0.05) were not affected (Fig. 6D). These results show that activation of 5-HT7Rs by the 
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blood-brain-barrier-penetrant specific agonist LP-211 can alleviate the emotional/affective pain 
behavior in mice experiencing neuropathic pain.   
 
4. Discussion 
On the cellular level chronic pain is established by persistent neuronal plasticity within the pain 
transmitting system (Basbaum et al., 2009; Costigan et al., 2009). Changes in cortical areas are of 
particular interest to understand the cognitive, motivational and emotional/affective aspects and 
deficits associated with the chronic pain condition (Apkarian et al., 2009; Simons et al., 2014).  
We recently demonstrated that activation of 5-HT7 receptors enhances HCN channel function and 
alleviates neuropathic pain, suggesting that neuromodulation in the forebrain might be a potential 
strategy for pain treatment. Here we studied the effects of LP-211, a highly specific 5-HT7R 
agonist that penetrates the blood-brain barrier. The use of this compound allowed non-invasive 
treatment of animals with neuropathic pain by acute i.p. injections. Our results revealed for the first 
time that mechanical sensitization of the injured hind paw can be reduced by systemic treatment 
with LP-211 and that at least part of the action can be attributed to a mechanism modulating the 
ACC. In contrast, the primary somatosensory cortex, a brain area that is important for the 
localization of nociception, was not involved in the action of LP-211. This suggests that LP-211 is 
not globally dampening the activity of cortical areas involved in pain processing. Nevertheless, it 
has to be determined which other pain-related areas might also be contributing to the overall 
analgesic effect. 5-HT7 receptors are expressed in the PAG and other brain areas as well as the 
spinal cord (Ciranna and Catania, 2014). Possible analgesic effects by activation of 5-HT7Rs in 
these areas have previously been reported (Li et al., 2014; Lin et al., 2015). For instance, although 
activation of 5-HT7Rs has no influence on acute pain behavior in naïve animals (Yesilyurt et al., 
2015), an up regulation of 5-HT7Rs in the dorsal horn of the spinal cord in neuropathic pain and a 
local analgesic effect of another 5-HT7R agonist (E-57431) has been shown (Brenchat et al., 2010). 
In contrast, the immunohistochemical staining of 5-HT7Rs in our case did not indicate such a 
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plastic change in receptor expression in the ACC in the neuropathic pain condition. In general, 
activation of 5-HT7Rs by descending serotoninergic pathways has been shown to be necessary for 
stress-induced analgesia. Moreover, the anti-hyperalgesic effects of morphine, of some 
antidepressants and non-opioid analgesic drugs also depend on 5-HT7Rs (Dam et al., 2014; Dogrul 
and Seyrek, 2006), suggesting that these receptors might be the final target of some established 
pain treatments as well as of the endogenous pain regulatory systems.  
LP-211 completely abolished the pain-induced shift in place preference in a place escape/avoidance 
paradigm. This behavioral assay depends on the ACC and it is thought to be related to the 
emotional/affective component of pain (LaBuda and Fuchs, 2000; LaGraize et al., 2004). This 
behavioral test assesses the averseness of neuropathic pain by exploiting the conflict between the 
desire to avoid pain versus the safety of an enclosed, dark location, which is usually preferred by 
the animal. Thus, we were able to show that LP-211 can reduce the emotional distress associated 
with chronic pain. Our results are consistent with previous findings reporting that LP-211 can 
modulate affective behavior and anxiety (Adriani et al., 2012) and extend these findings to the 
modulation of pain averseness.  
In the ACC, we were able to determine the mechanism of action of LP-211 on the cellular level. 5-
HT7R activation increases HCN function via the stimulation of adenylate cyclase and an increase in 
cAMP levels as has been demonstrated previously (Chapin and Andrade, 2001; Santello and 
Nevian, 2015; Tang and Trussell, 2015), resulting in decreased temporal summation of EPSPs and 
thus decreased cellular excitability of L5 pyramidal neurons. Importantly, we did not find any 
synaptic modulation suggesting that 5-HT7Rs are not involved in synaptic transmission. Previously, 
we have shown that there is also no influence on inhibitory interneurons and L2/3 pyramidal 
neurons in the ACC (Santello and Nevian, 2015). Alternative pathways downstream of 5-HT7R 
activation could be through protein kinase A (PKA) or other direct G-protein interactions (Perez-
Garci et al., 2013). We have previously shown that the activation of 5-HT7Rs has no further 
influence on cellular excitability when HCN channels are blocked, excluding an apparent 
alternative mode of action in L5 pyramidal neurons in the ACC (Santello and Nevian, 2015). 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
17 
In light of a potential translational utility of LP-211, the specificity of activating a particular 5-HT 
receptor subtype that decreases neuronal excitability might be beneficial compared to increasing 5-
HT levels in the brain globally with tricyclic antidepressants. Moreover, chronic LP-211 treatment 
may cause 5-HT7Rs upregulation and therefore might cause persistent beneficial effects, as it has 
been shown in other pathological models (Nativio et al., 2015; Ruocco et al., 2014). 
The 5-HT7 receptor has been little studied so far, mainly due to the lack of a specific agonist. The 
development of new brain-penetrant and specific 5-HT7Rs agonists is now helping shedding light 
on the pathophysiological role of this receptor, which has been documented to be present in several 
areas of the human nervous system including the anterior cingulate gyrus (Slassi et al., 2004). The 
results presented here together with the reported analgesic effects of activating 5-HT7Rs in the 
spinal cord, point to a central role for this receptor in pain modulation and suggest a novel and 
specific treatment strategy for chronic pain that acts both on spinal and supra-spinal targets.  
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Figure Legends 
Figure 1. 5-HT7 receptors and HCN channels co-localize in apical dendrites.  
A. Immunohistochemical staining of HCN1 (magenta, top) and 5-HT7Rs (green, middle) show a 
co-localization (white, bottom) of the two proteins in the main apical dendrites of L5 pyramidal 
cells (arrows) in the rostral ACC. The lower plot shows the intensity distribution for HCN1 and 5-
HT7Rs across the cortical layers. The solid black line represents a single exponential fit to the 
intensity profile of the HCN channel distribution. The dashed black line represents a Gaussian fit to 
the intensity profile of the 5-HT7R distribution. 
B. Enlarged view of apical dendrites shown in (A). 
C. Mechanical paw withdrawal threshold of mice subjected to CCI of the left sciatic nerve (CCI, 
red; n = 7) and sham operated animals (Sham, blue; n = 6). Only the paw on the injured side 
displayed a reduction of the withdrawal threshold indicating mechanical hypersensitivity. 
D. Length constant HCN of HCN1 distribution was significantly shorter for CCI as compared to 
sham operated animals. Error bars are S.E.M. *** p < 0.001. 
E. Fluorescence intensity and widths of 5-HT7R distribution was not different for CCI and sham. 
 
Figure 2. Effect of 5-HT7R activation by LP-211 on dendritic Ih and synaptic activity.  
A. Neurolucida reconstruction of a L5 pyramidal cell showing the position of the dendritic 
recording pipette. All recordings in this figure were performed on slices from CCI animals. 
B. Time course of the dendritic resting membrane potential (Vm) during bath application of the 5-
HT7 agonist LP-211 (27 nM) from the cell shown in B. Summary bar graph shows average values.  
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C. Example traces of the voltage response induced by a hyperpolarizing current step during 
baseline (red) and in the presence of LP-211 (blue) in a CCI animal. The average sag ratio showed 
a significant increase after bath application of LP-211 (n = 5).  
D. Time course of the EPSP amplitude during bath application of LP-211. Synaptic potentials were 
evoked by extracellular stimulation of the inner layer 1. Example traces show averaged EPSPs 
before and after the application of LP-211.  
E. EPSP amplitude and coefficient of variation (CV
2
) were not affected by LP-211 whereas the 
EPSP time integral was reduced (n = 10).  
F. Paired EPSPs evoked at 50 Hz before and in presence of LP-211. Bar graph shows that the 
paired-pulse ratio was reduced by LP-211, indicating a reduction in temporal summation (n = 10). 
Error bars are SEM. * p < 0.05, ** p < 0.01. 
 
Figure 3. LP-211 is more potent than 5-CT. 
A. Neurolucida reconstruction of a L5 pyramidal cell showing the somatic recording configuration. 
All recordings in this figure were performed on slices from CCI animals. 
B. Somatic voltage response to a 300 pA hyperpolarizing current step before (red) and after bath 
application of LP-211. Bar graphs show an increase of the sag ratio by LP-211 (n = 18).  
C. Somatic voltage response before (red) and after bath application of 5-CT. Bar graphs show that 
5-CT does not have an effect on the somatic sag ratio (n = 10).  
D. Normalized effect of LP-211 and 5-CT on the sag ratio.  
E. Normalized effect of LP-211 on the sag ratio in sham and CCI cells. Error bars are S.E.M. ** p 
< 0.01 *** p < 0.001. 
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Figure 4. Systemic LP-211 administration is analgesic for neuropathic pain.  
A. Experimental design for the i.p. injection of LP-211 or saline in CCI animals.  
B. Time course of the mechanical withdrawal threshold of mice subjected to CCI surgery and then 
tested after saline (upper graph, n = 6) or LP-211 injection (lower graph, n = 7).  
C. Withdrawal threshold of the injured paw normalized to the non-injured paw in saline (red) and 
LP-211 treated groups.  
D. Bar graph showing the drug effect of saline and LP-211 treated animals. Error bars are S.E.M. * 
p < 0.01. 
 
Figure 5. Effect of 5-HT7 antagonist injected in the ACC on LP-211 analgesia.  
A. Experimental design for the i.p. injection of LP-211 and concomitant cortical injection of SB-
269970, or saline, in CCI animals and subsequent von Frey testing of mechanical sensitization. 
B. Post hoc localization of the injection sites in the ACC by Alexa594 co-injection, ex vivo 
clearing of the brain and reconstruction with 3D-ultramicroscopy.  
C. Time course of the mechanical withdrawal threshold of mice subjected to CCI surgery and 
treated with LP-211 after ACC injection of saline solution (upper graph, n = 6) or SB-269970 
(lower graph, n = 6). At time t = -60 min LP-211 was i.p. injected and at t = -45 min the saline or 
SB269970 solution was injected.  
D. Withdrawal threshold of the injured paw normalized to the non-injured paw after LP-211 
injection and subsequent injection of saline (blue) or SB-269970 (purple) in the ACC.  
E. Bar graph showing the drug effect of LP-211 treated animals after ACC injection of saline or 
SB-269970 showing a significant effect of 5-HT7R blockade in the ACC on mechanical 
sensitization. Saline (n = 4) or SB-269970 (n = 7) injection into the ACC without LP-211 had no 
analgesic effect by itself. Error bars are S.E.M. * p < 0.05. 
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F. Post hoc localization of the injection sites in S1 by Alexa594 co-injection, ex vivo clearing of 
the brain and reconstruction with 3D-ultramicroscopy. 
G. Withdrawal threshold of the injured paw normalized to the non-injured paw after LP-211 
injection and subsequent injection of saline (blue) or SB-269970 (purple) in S1.  
H. Bar graph showing the drug effect of LP-211 treated animals after S1 injection of saline or SB-
269970 showing no effect of 5-HT7R blockade in the S1 on mechanical sensitization. Saline (n = 7) 
or SB-269970 (n = 8). 
 
Figure 6. LP-211 normalizes emotional pain behavior.  
A. Experimental design of the PEAP. The mouse can freely move between a light and dark 
compartment. The injured paw is stimulated in the dark compartment and the uninjured paw in the 
light compartment. Stimulation of the corresponding paw was repeated every 15 s. The heat maps 
on the right illustrate the time spent in each position 20 – 30 min after the beginning of the 
stimulation in a saline (top) and LP-211 (10 mg/kg, bottom) treated animal. In the saline treated 
condition, the animal spent less time in the preferred dark compartment.  
B. The relative time spent in the light compartment is plotted as a function of time. 20 – 30 min 
after the beginning of the stimulation of the corresponding hind paw, saline treated CCI animals 
showed a switch in place preference (red, n = 7). This switch was absent in LP-211 treated animals 
(blue, n = 8). The dashed line refers to the average of the first 10 min of the stimulation in the two 
conditions (37.3%).  
C. 10 min before the beginning of the stimulation the animals were allowed to freely explore the 
two compartments. The bar graph shows the relative time spent in the light compartment of saline 
and LP-211 treated animals. Open circles indicate individual experiments. LP-211 injection had no 
influence on the overall anxiety level.  
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D. Average velocity and total distance covered of the animals during the recording period of 40 
min. No differences were found for these parameters in saline and LP-211 treated animals. Error 
bars are S.E.M. * p < 0.05. 
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Fig. 6 
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Highlights 
 Anterior cingulate cortex contributes to the emotional/affective distress in chronic pain 
 Dysfunction of HCN channels increase cellular excitability in chronic pain 
 LP-211 is a brain-penetrant 5-HT7 receptor agonist that enhances HCN channel function 
 LP-211 alleviates the sensory and affective/emotional pain behavior in neuropathic animals 
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